CA1304681C - Stable biologically active fluorochemical emulsions - Google Patents

Stable biologically active fluorochemical emulsions

Info

Publication number
CA1304681C
CA1304681C CA000541959A CA541959A CA1304681C CA 1304681 C CA1304681 C CA 1304681C CA 000541959 A CA000541959 A CA 000541959A CA 541959 A CA541959 A CA 541959A CA 1304681 C CA1304681 C CA 1304681C
Authority
CA
Canada
Prior art keywords
specific binding
fluorochemical
emulsion
emulsions
droplets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000541959A
Other languages
French (fr)
Inventor
Dean S. Milbrath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Application granted granted Critical
Publication of CA1304681C publication Critical patent/CA1304681C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/804Radioisotope, e.g. radioimmunoassay
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Colloid Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

Abstract Fluorochemical emulsions comprised of a fluorochemical droplet discontinuous phase and aqueous continuous phase with at least one specific binding species immobilized on the fluorochemical droplets are shown. The emulsions may include a primer material to couple to specific binding species to the fluorochemical droplets.
The emulsions may be used in diagnostic procedures or biochemical reactors where binding of the immobilized specific binding species to its binding partner is desired.
The droplets may also incorporate a species which is detectable by spectrophotometric, fluorometric or colormetric means or a precursor to a detectable species.

Description

6~

STABLE E~IOLOGICALLY P~CTIVE FLUOROC~IEMICAL Et~ULSIOl`lS

Field of the Invention The present invention relates to fluorochemical 5 emulsions which carry on the droplet surface one member of a specific binding pair. The novel emulsions of this invention are useful as diagnostic supports and as supports for biochemical reactions.

10 Background of the Invention Supports for antigen/antibody assays and biochemical reactions are typically latex beads, paper, fixed red blood cells and insoluble polymers such as dextran and polystyrene. ~n these assays and biochemi.cal 15 reactions at least one member of a specific binding pair (hereinafter a "specific binding species") is immobilized on a support and thereafter subjected to chemical reactions, physical manipulation or both in a manner that ultimately results in its binding (transitory or permanent) 20 of the other member of the specific binding pair to the specific binding species. This coupling of the two members of the specific binding pair is useful to detect qualitatively or quantitatively the presence of one o the species in a sample as in a competitive assay, an 25 immunoassay, a protein binding assay. Similarly, the binding of the two members of the specific binding pair can be used to take advantage of the inherent properties of one of the species, e.g., an enzymatic property.
A persistent problem in designing assays and 30 reaction systems i5 the difficulty in immobilizing the specific binding species on the support so that it will withstand washings and remain on the support under the contemplated chemical conditions. Another problem is denaturing the specific binding species pair, i.e., 35 reversing prematurely the binding of the two species such that the bound member disassociates from the immobilized member or the immobilized member and the bound member ~3 - - ~ ' ' ~3~f~6Bl disassociate from the support. ~eactivity of the support under the contemplated conditions of use, resulting in nonspecific binding of constituents in a test sample, is another persistent problem.
Microcapsules have been suggested ~or use as supports in immune response assays. UK patent Application 2,079,937 A (published 27 January 1982) and UK patent Application 2,079,936 A tpublished 27 January 1982) both describe making microcapsules with crosslinked wall 10 materials encapsulating an oily core substance. ~unctional groups with sites for binding an antigen or antibody are attached to the wall by a crosslinking agent.
Fluorocarbon emulsions have been suggested for use as in vivo erythrocyte substitutes. Some fluorocarbon 15 emulsions seem to have good oxygen transport characteristics and appear to be nontoxic and safely metabolized. Other fluorochemical emulsions have been shown to be toxic in laboratory animals or not metabolized and eliminated. Geyer describes various emulsions in 20 Chapter 1, "The Design of Artificial slood Substitutes", Dru~ Design, Vol. VII Academic Press, N.Y. (1976) and in "Whole Animal Perfusion with Fluorocarbon Dispensors"
Federation Proceedings, Vol. 29 No. 5, p. 1758, (1970).
Serum albumin, phospholipids (including lecithin), and 25 surfactants such as Pluronic-F68 (Wyandotte Chemical Corp., Wyandotte, Mich) have been used as emulsifying agents.
For use as artificial blood Sloviter in U.S. Pat.
No. 4,423,007, has suggested emulsions of perfluoro compounds coated with a non-antigenic lipid, preferably egg 30 yolk phospholipid or lecithin, in aqueous medium. He reports in U.S. Pat. No. 4,397,870 that the duration of effective droplet levels in the bloodstream is brief owing to the apparent removal of the lecithin coating and exposure of the perfluoro droplet surface in the 35 bloodstream. Infusion of the patient who has previously received an infusion of an emulsion of coated droplets with the same substance used to coat the perfluoro compound droplet is recommended.

~3~ 6~31 Sloviter in "Erythrocyte Substitute for Perfusion of srain" Nature Vol. 216, ~ov. lg67, 458, has also suggested dispersing a perfluoro compound in a simulated blood plasma compound of 8% bovine serum albumin in Krebs 5 Ringer bicarbonate buffer. After the emulsion was formed and sedimented all soluble protein was washed away. The sedimented material was analyzed and found to contain about 5% protein.
The Japanese have also been active in the field 10 of artificial blood~ U.S. Pat. No. 4,252,827 is directed to fluorocarbon compound emulsions that are sufficiently stable to be kept for a long period of time without change in droplet size and can be mixed with plasma extenders such as dextran and hydroxyethyl starch. It describes an 15 emulsion in an organic medium having a perfluorocarbon compound with 9 to 11 carbon atoms, a perfluoro-tert-amine having 9 to 11 carbon atoms, a surfactant having a molecular weight of about 2,000 to 20,000, a phospholipid and at least one fatty acid.
The effect of perfluoro organic compound emulsions on serum proteins and phosolipids has been studied by V.V. Obraztsuv et al. "sinding of Proteins and Phospholipid by Emulsion of Perfluoro Organic Compounds"
Ftoruqlerodrye Gazoperrnosyaschchie Sridy [531 FA5] 1984 25 147-52 (Russ). The protocol followed by these authors is not clear. They appear to have analyzed the amount of protein and phospholipids removed from solution only at equilibrium conditions. They do not report any experiments attempting to wash adsorbed protein and phospholipid off 30 the emulsion droplets. They state "irreversible and denaturant character of binding of proteins by the hydrophobic surface raises the question to what extent the concentration of the proteins in the blood might be decreased as a result of the extensive blood substitution 35 with PFOC emulsion."

.. . . . . . . . .

13(~68 ~' -~- 60557-3262 Summarv of the Inventlon The present invention provides an in vitro specific binding process comprising, a. providing in vi~ro an emulsion comprising an aqueous continuous phase, a fluorochemical droplet discontinuous phase comprising a fluorochemlcal liquld and a fluorinated surfactant soluble in said fluorochemical liquid, and a specific binding species immobilized on the fluorochemical droplets, wherein the emulsion is substantially stable to centriFugation at 30,000 x g for 15 minutes; and b. contacting the fluorochemlcal droplets and immobilized specific binding species with an aqueous solution containing the specific binding partner of the specific binding species for a period of time sufficlent to permit binding between the specific binding species and the specific binding partner.
The present invention is a stable emulsion having an aqùeous continuous phase and a fluorochemical droplet discontinuous phase. At least one specific binding species is immobilized at the surface of the fluorochemical droplets without loss of speclfic binding capability. As used herein the term "specific binding species" refers to one member of a specific binding pair. The emulsions of the present invention are easily prepared and surprisingly stable over long periods of time. The emulsions withstand washings without loss of specific binding capability.
The relative inertness of fluorochemical to biological molecules as compared to conventional supports makes them ideally suited for use in a wide variety of circumstances. Representative C

~3~ 8~

-4a- 60557-3262 examples of specific binding ~pecies wh:L~h can be immobilized on fluorochemical droplets include one member o~ an antigen/antibody pairs where the antigen is a naturally occurrinq or synthetlc protein, peptide, polysaccharide, lipid, nucleic acid, organic polymer, an antigenic fragment of these materials, an infectious `~, ~L3~

60557-3~62 agent such as bacteria or virus or a portion of their cell surface, a hapten such as a drug, hormone, or organic molecule and combinations and derivatives thereof; a molecule or segment of naturally occurring or synthetic DNA or XNA; an enzyme such as alkaline phosphatase, peroxidas~, or beta-galactosidase, luciferase, urease, or other enzymes selected from oxidoreductases, transfereases, hydrolyases, kinases or lyases; another reaction catalyst; a lectin; a sugar; a cell surface marker or receptor;
and a therapeutic substance such as a drug, plant extract, hormone or metabolites of these; an endotoxin; the other member of the specific binding pair for each of the foregoing; and other components of specific binding reaction schemes such as dyes, fluorescent molecules, or components which in specific binding reaction schemes can be used to produce color, fluorescence, phosphorescence, chemiluminescence or other detectable products.
Another aspect of the invention involves immobilization of combinations of different specific binding species on the same emulsion droplets. Emulsions having a combination of specific binding species and other components of their specific binding reaction scheme are particularly useful in diagnostic systems.
Thus one member of an antigen/antibody binding pair and a material which is or reacts to form a detectable product such as an enzyme, dye, fluoroescent molecule, or chemiluminescent reagent can be independently immobilized on emulsion droplets. Immobilization of multiple specific binding species allows the immobilization of the separate components of an enzyme cascade which can be used to determine the presence and amount of a substance. For example B

1304~
-5a-glucose can be detected with the enzymes glucose oxidase and peroxidase linked to the same emulsion droplet.
The specific binding species may be immobilized on the fluorochemical droplet by direct adsorption at the droplet/aqueous interface. Alternatively a primer material may be used. A
"primer material" is a material which has the ability to couple a specific binding species to a fluorochemical droplet. Naturally occurring or synthetic polymers with amine, carboxyl, mercapto, or other functional groups capable of specific reaction with coupling agents and highly charged polymers are preferred. The specific binding species may be immobilized by covalently bonding it to a primer material and adsorbing the conjugate at the inter-face of the discontinuous and the continuous phases.
Alternatively the specific binding species may be adsorbed to a primer material and the resulting comple~ adsorbed at the interface of the continuous and discontinuous phases. The same result can be achieved by forming an emulsion with an aqueous continuous phase and a fluorochemical discontinuous phase using a primer material as an emulsifying agent. Then the biologically active moiety may be adsorbed or conjugated to the primer material at the interface of the continuous and discontinuous phases.
Among preferred primer materials are albumins, casein, whole sera, fibrinogen, collagens, and naturally occurring and synthetic poly(amino acids) and charged polysaccharides.
Yet another aspect of the invention involves incorpora-ting a "dye" into the fluorochemical droplet.

.~

I'Dyes" as used herein are species which can be detected by spectrophotometric, fluorometric or colorimetric means.
The process of the present invention involves providing an in vitro emulsion having an aqueous continuous 5 phase and a fluorochemical discontinuous phase. At least one specific binding species is immobilized on the fluorochemical droplets. The ~luorochemical droplets and immobilized specific binding species are contacted with an aqueous solution containing the speci~ic bi~ding partner of 10 the specific binding species for a period of time sufficient to permit binding of the specific binding species to its partner. The process is preferably used in diagnostic procedures such as agglutination assays, sandwich or reverse inhibition enzyme immunoassays or radio lS immunoassays, or a protein binding assay.

Detailed Description The emulsions of the present invention may be made with a large variety of materials.
~ variety of fluorochemical liquids may be used.
Suitable fluorochemical liquids include straight and branched chain and cyclic perfluorocarbons, straight and branched chain and cyclic perfluoro tertiary amines, straight and branched chain and cyclic perfluoro ethers and 25 thioethers, chlorofluorocarbons and polymeric perfluoro ethers and the like. Although up to 50%
hydrogen-substituted compounds can be used, perhalo compounds are preferred. Most preferred are perfluorinated compounds. Exemplary fluorochemicals useful in the present 30 invention are commercially available materials such as the fluorochemicals sold with the trademarks Kel-FR and Fluorinerts (3M, St. Paul, Minnesota), FreonsR and Series E (Dupont, Wilmington, Delaware) and Fomblins (Montedison, Italy).
Although any fluorochemical liquid i.e. a substance which is a liquid at about 20C at atmospheric pressure, can be used to prepare a fluorochemical emulsion O~

of the present invention, for many purposes emulsions with longer extended stability are preferred. In order to obtain such emulsions, fluorochemical liquids with boiling points above 30C are preferred. Preferably the 5 fluorochemical liquids have boiling points above 50C, and most preferred are fluorochemical liquids with boiling points abvve about 100C.
Suitable fluorochemical liquids include perfluorodecalin, perfluoro-n-pentane, perfluoromorpholine, 10 perfluorotriamylamine, perfluorodimethylcyclohexane, perfluorodicyclohexyl ether, perfluoro-n-butyltetrahydro-furan, perfluoro-n-octyl bromide, perfluorotri-n-butyl-amine, and compounds which are structurally similar to these compounds and are partially or fully halogenated 15 (including at least some fluorine substituents) or partially or fully perfluorinated.
Emulsifying agents, for example surfactants, may be used to facilitate the formation of emulsions.
Typically, aqueous phase surfactants have been used to 20 facilitate the formation of emulsions of fluorochemical liquids. One of the primer materials such as albumins, polysaccharides, and phospholipids may be used as an emulsifying agent. Other known surfactants such as Pluronic F-68, a block copolymer of -O(CH2)2-O-(CH2)2-0-25 and -O- ( C~2 ) 3 -O- ( CH2 ) 3 -- ~ may be used.
Some examples of suitable surfactants are anionics, such as those sold with the trade names:
HamposylTM L30 (W.R. Grace Co., Nashua, NH), Sodium dodecyl sulfate, Aerosol 413 (American Cyanamid Co., Wayne, NJ), Aerosol 200 (American Cyanamid Co.), Lipoproteol LCO (Rhodia Inc., Mammoth, NJ), Standapol SH 135 (Henkel Corp., Teaneck, NJ), FizulTM 10-127 (Finetex Inc., Elmwood Park, NJ), and CyclopolTM SBFA 30 (Cyclo Chemicals Corp., Miami, FL);

.

amphoterics, such as those sold with the trade names:
~eriphatTM 170 (Henkel Corp.), Lonzaine JS (Lonza, Inc.), MiranolTM C2M-SF (Miranol Chemical Co., Inc., Dayton, NJ), Amphoterge~M w2 (Lon~a, Inc.), and Amphoterge M 2WAS tLonza, Inc.);

non-ionics, such as those sold with the trade names:
Pluronic~M F-68 (BASF Wyandotte, Wyandotte, MI), PluronicTM F-127 ~BASF Wyandotte), Bri j~M 35 (ICI Americas; Wilmington, DE), Triton~M x-100 (Rohm and Haas Co., Philadelphia, PA), Brij~M 52 (ICI Americas), SpanTM 20 (ICI Americas), Gene rolT M 122 ES (Henkel Corp.), Triton M N-42 (Rohm and Haas Co.,), TritonT~ N-101 (Rohm and Haas Co.,), TritonTM X-405 (Rohm and Haas Co.,), TweenTM 80 (ICI Americas), TweenTM 85 (ICI ~mericas), and ~rij~M 56 (ICI Americas).
These surfactants' are used alone or in combination in 25 amounts of 0.10 to 5.0% by weight to assist in stabilizing the emulsions.
Fluorinated surfactants which are soluble in the fluorochemical liquid to be emulsified can also be used.
Suitable fluorochemical surfactants include perfluorinated 30 alkanoic acids such as perfluorohexanoic and perfluorooctanoic acids and amidoamine derivatives thereof such as C~FlsCONH(CH2)4N(CH3 )2 and l,l-dihydroperfluoro-alcohols such as l,l-dihydroperfluoro-n-octanol. These surfactants are generally used in amounts of 0.01 to 5.0%
35 by weight, and preferably in amounts of 0.1 to 1.0%.
Other suitable fluorochemical surfactants include perfluorinated alcohol phosphate esters and their salts;

~0557-3262 perfluorinated 6ulfonamide alcohol phosphate e~ter~ and their salt~; perfluorinated alkyl ~sulfonamide alkylene quaternary a~nonium salts; N,N-(carboxyl-su~stitut2d lower alkyl) perfluorinated alkyl sulfonamides; and mixtur~s thereofO As u~ed herein, the term "perfluorinated" means that the surfactant contains at least one pezfluorinated alkyl group.
Suitable perfluorinated alcohol phosphate esters include the free acids of the diethanolamine salts oP mono-and bis( lH, lH, 2H, 2~-perfluoroalkyl)phosphates. Ths phosphate salts, available under the trade-mark "Zonyl RP"
(E.I. Dupont de Nemours and Co., Wilmington, Del.), are converted to the corresponding free acids ~y known methods.
Suitable perfluorinated sulfonamide alcohol phosphate 15 esters are described in U.S. Pat. Wo. 3,094,547, and have the general formula:

[RfS02N(R)R'O]mP(oH)3-m wherein R is hydrogen or an alkyl group having 1 to about 12 carbon atoms, preferably from 1 to 6 carbon atoms; R' is an alkylene bridging group containing 2 to 12 carbon atoms, preferably from 2 to 8 carbon atoms; Rf is 25 perfluoroaliphatic CnF2n+1 or perfluorocycloaliphatic CnF2n 1 (n i~ an integer from 1 to 18, prefer~bly from 6 t~
12); and m is an integer from 1 to 3. Although each of the mono-, di- and triesters are useful, the diester is most readily available commercially. Suitable perfluorinated 30 sulfonamide alcohol phosphate esters and salts of these include perfluoro-n-octyl-N-ethylsulfonamidoethyl phosphate, bis(perfluoro-n-octyl-N-ethylsulfonamidoethyl) phosphate, the ammonium salt of bis(perfluoro-n-octyl-N-ethylsulfonamidoethyl)phosphate, 35 bis(perfluorodecyl-N-ethylsulfonamidoethyl)phosphat0 and bis(perfluorohexyl-N-ethylsulfonamidoethyl)phosphate.

` D

13~

The preferred formulations use Pluronic F-58 as the aqueous surfactant in phosphate buffered saline and perfluoroamidoamines and perfluorodihydroalcohols as the fluorochemical surfactants.
S The fluorochemical emulsion can be prepared with or without a primer material. Suitable primer materials include proteins such as albumins (e.g. bovine serum albumin and ovalbumin~, casein, whole sera such as normal human serum, fibrinogen, collagens, synthetic poly(amino acids) e.g. poly(lysine-phenylalanine) and polylysine.
Primer materials rich in lysine content produce emulsions droplets which are highly active in coupling reactions.
Use of copolymers which have a one to one ratio of lysine with a hydrophobic amino acid such as alanine or phenylalanine as primer materials results in a very high concentration of amino groups available for coupling reactions. These lysine-hydrophobic amino acid copolymers are adsorbed tightly with the hydrophobic residues interacting with the fluorochemical fluid phase. In some cases, however, the use of the copolymer alone as a primer material may result in crosslinking of emulsion droplets during coupling reactions with specific binding species. A
mixture of bovine serum albumin and copolymer alleviates the crosslinking problem, however the amount of specific binding species that can be coupled is also reduced. Other suitable primer materials include naturally occurring or synthetic polymers which are highly charged such as charged polysaccharides e.g. heparin, dextran sulfate, DIMA (a dimethylamine adduct of expoxidized polybutadiene as disclosed in U.S. Patent No. 4,210,722), protamine sulfate, nucleic acids and the like.
The emulsions of the present invention may be prepared by various techniques. One method is sonication of a mixture of a fluorochemical liquid and an aqueous solution containing a suitable primer material or specific binding species. Generally, these mixtures include a surfactant. Cooling the mixture being emulsified, ~ . - . . ... ... , . . . ~ .

13(~

minimizing th~ concentration of surfactant, and buf~ering with a saline buffer will maximize both retention o specific binding properties and the coupling capacity of the primer material. These techniques provide excellent 5 emulsions with high activity per unit of absorbed primer material or specific binding species.
When high concentrations of a primer material or specific binding species coated on fluorochemical droplets are desired, the mixture should be heated during sonication, the mixture should have a relatively low ionic strength, and the aqueous solution should have a moderate to low pH. Too low an ionic strength, too low a pH and too much heat in some cases may cause some degradation or loss of all of the specific binding properties of the specific lS binding species or the coupling capacity of the primer material. Careful control and variation of the emulsification conditions will optimize the properties of the primer material or the specific binding species while obtaining high concentrations of coating. Variation of 20 ionic strength, pH, and temperature have been found to be particularly valuable where bovine serum albumin is the primer material.
The quality of the emulsions obtained can be evaluated by conventional techniques such as visual 25 observation, nephelometry, coulter counter measurement or spectrophotometric measurement. When suitable indicators are included in the emulsion components, such as dyes or fluorescent and chemiluminescent markers, the emulsion droplets can be observed by the properties of these 30 materials. The useful emulsions may have a wide range of mean droplet diameters, e.g., from as small as 0.01 microns to as large as 500 microns. The droplet sizes can be controlled and varied by modifications of the emulsification techniques and the chemical components.
While preparation of emulsions by sonication has been acceptable, some degree of variability of droplet size distribution of the droplets is observed. An alternative . ~ . . .. . . . . . . . . . . . . .

~30~6~

method of makiny the emulsions involves directing high pressure streams of mixtures containing the aqueous solution, a primer material or the specific binding species, the fluorocarbon liquid and a surfactant (if any) 5 so that they impact one another to produce emulsions of narrow droplet size distribution and small droplet size.
The MicrofluidizerTM apparatus tMicrofluidics, Newton, MassO) is used to make the preferred emulsions. The apparatus is also useful to process emulsions made by 10 sonication or other conventional methods. Yeeding a stream of droplets through the MicrofluidizerTM apparatus yields emulsions having narrow droplet size distribution and small droplet size.
The specific binding species may be immobilized 15 on the fluorochemical droplet surface by direct adsorption or by chemical coupling. Examples of specific binding species which can be immobilized by direct adsorption include antibodies, protein A, and enzymes. To make such an emulsion the specific binding species may be suspended 20 or dissolved in the aqueous phase prior to formation of the emulsion. Alternatively, the specific binding species may be added after formation of the emulsion and incubated with agitation at room temperature (25C) in a pH 7.0 buffer ~typically phosphate buffered saline) for 12 to 18 25 hours.
Where the specific binding species is to be coupled to a primer material, conventional coupling techniques may be used. The specific binding species may be covalently bonded to primer material with coupling 30 a~ents using methods which are known in the art. One type of coupling agent uses a carbodiimide such as 1-ethyl-3-(3-N,N-dimethylaminopropyl)carbodiimide hydrochloride or 1-cyclohexyl-3-(2-morpholinoethyl~carbodiimide methyl-p-toluenesulfonate. Other suitable coupling agents include 35 aldehyde coupling agents having either ethylenic unsaturation such as acrolein, methacrolein, or 2-butenal, or having a plurality of aldehyde groups such as . . . . . . . . . . . .. . . . . . .

O~

glutaraldehyde, propaneclial or hutanedial. Other coupling agents include 2-iminothiolane hydrochloride, bifunctional N-hydroxysuccinimide esters such as disuccinimidyl suberate, disuccinimidyl tartrate, 5 bis[2-(succinimidooxycarbonyloxy)ethyl]sulfone, disuccinimidyl propionate, ethylene glycolbis(succinimidyl succinate); heterobifunctional reagents such as N-(5-azido-2-nitrobenzoyloxy)succinimide, p-azidophenylbromide, p-azidophenylglyoxal, 4-fluoro-3-nitrophenylazide, 10 N-hydroxysuccinimidyl-4-azidobenzoate, m-maleimidobenzoyl N-hydroxysuccinimide ester, methyl-4-azidophenylglyoxal, 4-fluoro--3-nitrophenyl azide, N-hydroxysuccinimidyl-4-azidobenzoate hydrochloride, p-nitrophenyl 2-diazo-3,3,3-trifluoropropionate, 15 N-succinimidyl-6-(4~-azido-2~-nitrophenylamino)hexanoate, succinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate, succinimidyl 4-(p-maleimido-phenyl)butyrate, N-succinimidyl(4-azidophenyldithio)-propionate, N-succinimidyl 3-(2-pyridyldithio)propionate, 20 N-(4-azidophenylthio)phthalamide; homobifunctional reagents such as 1,5-difluoro-2,4-dinitrobenzene, 4,4'-difluoro-3,3'-dinitrodiphenylsulfone, 4,4'-diisothiocyano-2,2'-disulfonic acid stilbene, p-phenylenediisothiocyanate, carbonylbis(L-methionine p-nitrophenyl ester), 25 4,4'-dithiobisphenylazide, erythritolbiscarbonate and bifunctional imidoesters such as dimethyl adipimidate hydrochloride, dimethyl suberimidate, and dimethyl 3,3'-dithiobispropionimidate hydrochloride. Covalent bonding of a specific binding species to the primer 30 material can be carried out with the above reagents by conventional, well-known reactions, for example, in the aqueous solutions at a neutral pH, at temperatures of less than 25C for 1 hour to overnight.
In some applications the emulsions of the present invention are more useful if the fluorochemical droplets incorporate dye which can be detected by spectrophotometric, fluorometric, or colorimetric means.

~o~
1~ 60557-3262 For example, agglutinatlon end points are more easily observed with t}le naked eye when the fluorochemical droplet is colored. Suitable dyes useful for this purpose are dyes sufficiently soluble in fluorinated liquids ~o color the 5 liquid. The preferred dyes are soluble in perfluorinated liquids. Such dyes will typically possess one or more soluhilizing groups such as halogenated side chains or preferably a perfluorinated side chain such as a perfluoroalkyl or perfluoroalkyl ether side chain or 10 perfluorinated cyclic group. Some examples of suitable dyes are the perfluoroalkylated phthalein, phthalocyanine, rhodamine, and quinophthaline dyes described in U.S. Patent No. 3,281,426.
Representative dyes described in that patent ar~ thioindigo 15 (pink), pyranthrone (orange), violanthrone ~dark blue), isoviolanthrone (violet), and Tiers~ Blue, a copper phthalocyanine substituted by perfluoroalkyl groups:

n-C8F17 N '~ ~ N

n-C8F17~ -cu-N~n-c8Fl7 n C8F17 . A substituted methyl red analog with a perfluoroalkyl group is: 5 n C8 17S 3 ~-N=N ~-N( CH3 ) 2 Other suitable dyes are perfluoroalkyl-beta-diketone lanthanide complexes such as, ~L~O~

r ~1 Ln ~H
f _ 3 wherein R and X1f are perfluoroalkyl or perfluoroaryl and the like.
The soluble dyes may be dissolved in the lO fluorochemical liquid to be emulsified before emulsification by simple mixing, optionally with heating.
Alternatively, the addition of the soluble dye and the emulsification may be carried out simultaneously using standard emulsifica~ion techniques such as sonication and 15 mechanical emulsification as obtained using a motorized ~rench press, Model FA-078 (available from SLM Instruments, Inc., Urbana, Illinois). Dye can be added to the emulsions after the formation of the emulsions, although this operation may be more difficult because the primer material 20 or the specific binding species may act as a barrier.
Combinations of different dyes in separate droplets offer the possibility of preparing emulsions of any color. Selective removal of one color of droplets due to an antibody-antigen aggregation reaction for example, 25 would cause a change in the apparent color of the emulsion.
Also dyed droplets which are adhered to a dipstick, due to an antigen-antibody reaction, would produce a color on a dipstick. Both of these approaches have the potential of producing an easily interpreted, qualitative endpoint for a 30 number of immunoassays.
Dye precursors may also be used. For instance, color forming agents may be associated with the surface of droplets so that they can couple to an appropriate material to form dyes (a type of color coupling technique). This 35 could be accomplished using the diazo salt used to produce the perfluoroalkyl methyl red material described above.
Further aspects of the invention, including the process of using the emulsions, will be apparent from the following non-limlting examples.

? `~
~_`

~L3~)~6l3~

Example 1 In order to compare the formation of fluorochemicals emulsions in a standard way, each of fluorochemicals fluids shown in Table 1 was emulsified by 5 sonication in an ice bath cooled rosette cell for five minutes. Each fluorochemical liquid (100 microliters) was dispersed at a concentration of 1 volume % in 10 ml of aqueous saline, phosphate buffered to pH 7 and containing 0.5~ by weight Pluronic F-68 as a surfactant.
These solutions were evaluated after one day and again after 7 days for droplet size by recording the amount of sedimentation. Droplet size was determined on a qualitative basis under 400X magnification with dark field illumination after 1 and 7 days.
The low boiling perfluorocarbons FC-78 and FC-88 and the chlorofluorocarbons Freon 113 and Rel-F1 formed poorer quality emulsions than the rest of the substances.
The presence of nitrogen or oxygen in the fluorinated compounds appeared to result in increased emulsion stability and decreased droplet size in this group of substances.

- .. . . . . . . . . . . .

PERFLUORINATED LIQUID `~

1. Decalin (PP-5: DuPont) 2. n-Pentane (FC-88: 3M~
3. Morpholine (FC-78: 3M) 4. Tri-n-amylamine (FC-70: 3M) 5. Dimethylcyclohexane (FC-82: 3M) 6. Polyether E-2 (DuPont) 7. Polyether E-5 (DuPont) 8. Kel F-1 (3M) (Cl-(CF2-CClF)2-Cl) 9. Fomblin LS
(Montedison) (-OCIF-CF2)m-O-(CF2-O)mC
10. Freon 113 (DuPont) (C13CCF3) 11. Dicyclohexyl ether (DCE) 12. Octyl Bromide (OB) 13. Tri-n-butylamine (FC-43: 3M) 14. C-8 Cyclic ether (FC- 75: 3M) 15. C-8 Mixture (FC-77: 3M) 35 ~
A fluorochemical cosurfactant consisting of perfluoro-n-octanoic acid or perfluoroamidoamine, .~
~. ~

~3~4~

C7Fl5C(O)NH(CH2 )qN(CH3 )2 was dissolved in each of the fluorochemical fluids of Table I before the emulsion was prepared as in Example 1. The perfluoroacid-containing fluorochemicals were emulsified in the surfactant buffer 5 described in ~xample 1 with 0.05 to 0.1% bovine serum albumin ( BSA) solution and the perfluoroamidoamine-containing fluorochemicals were emulsified in a 0.05% DIMA solution. These emulsions were also evaluated for droplet size and sedimentation as 10 described in Example 1. Each of the fluorochemicals listed in Table 1 was successfully dispersed as an emulsion with these fluorocarbon and polymer cosurfactants. These emulsions appeared to be more stable and their droplet size was generally smaller than the emulsions prepared without 15 the cosurfactants in Example 1.

Example 3 The emulsions prepared in Example 2 were analyzed for the amount of fluorochemical dispersed, the amount of 20 BSA or DIMA bound to the surface of the droplets, and the sizes of the droplets produced. Prior to this analysis the emulsions were separated from free protien by addition of a saturated solution of ammonium sulfate, 1:1 volume:volume, centrifugation of the precipitate and resuspension of the precipitate in fresh buffer-surfactant solution. This was followed by centrifugation at 30,000 x g for 15 minutes and resuspension in fresh buffer-surfactant solution two additional times.
The fluorochemical content of these emulsions was determined by gas chromatographic analysis on an OV-101 packed column, 6 feet x 0.125 inch. The fluorochemical content was determined by comparison with a standard curve prepared by injection of known amounts of FC-43. Since the response of the flame ionization detector (FID) varied somewhat to the various fluorochemicals emulsified, the fluorochemical content calculated also varied accordingly.

, . . . . .. . . . . . . . . . . . . .

4~

The amount of BSA and DIMA on the surface of the emulsion droplets was determined by the Bradford method using Coomassie slue G-250 and a standard curve prepared with known amounts of sSA and DIMA.
The size of emulsion droplets was examined by microscopic evaluation ~400 x under dark field illumination) and assigned a numerical score on days one and seven after preparation. A numerical score was determined by assigning a value of 1, 2, 3, 4, 5, or 6 to emulsion droplets judged to be about the size of 200, 330, 460, 800, 1200, or above 2500 nanometers, respectively, by comparison to sized polystyrene latex beads (Sigma Chemical). Using a representative microscopic field of each sample, the number of droplets of a particular size range were multiplied by their size value. The final score for an emulsion was the sum of these size scores divided by the total number of droplets. When an emulsion sample appeared to have a substantial number of droplets aggregated into clumps, the emulsions were noted as 20 aggregated and were not scored further.
The analytical results and scores assigned by microscopic examination of these emulsions are shown in Table 2. This data shows that significant amounts of BSA or DIMA are present on the droplet surface after 25 emulsification and that it is not removed by repeated washing with fresh buffer-surfactant. The amount of BSA or DIMA found bound to the fluorochemical (milligrams per milliliter of fluorochemical emulsion) is greatest in dispersions of FC-43, FC-75, E-2, E-5, and DCE, which are 30 fluorochemicals with heteroatoms (nitrogen or oxygen).
Also, more ssA is bound than is DIMA for all formulations.
The size data indicates emulsions formulated with BSA showed a tendency to aggregate into clumps of droplets while the DIMA emulsions did not. Additionally, the change 35 in numerical score of some of the emulsions over the 7 day period indicates that these preparations are dynamically approaching a more stable size distribution for the particular formulation.

.. , . . j . .. . . . . . . . . . . .

~3~61~

Fluorocarbon Emulsions Prepared for Quantitative Comparison Fluoro-Micro Protein carbon 5 Fluoro- Exam Content Content carbon Emulsifier 1 day 7 day mg %
PP-5 BSA-Acid 1.58 1.58 7.53 2.97 DIMA-Amidoamine 1.58 1.67 5.93 2.74 FC-70 B5A-Acid 1.88 Agg 9.95 0.71 DIMA-Amidoamine 1.88 1.59 4.74 0.68 FC-82 BSA-Acid 1.54 1.43 9.86 1.07 DIMA-Amidoamine 1.54 1.5g 4.74 0.96 E - 2 BSA-Acid 1.65 1.82 19.0 0.53 DIMA-Amidoamine 1.65 1.50 8.85 0.67 15 E-5 BSA-Acid 2.06 Agg 13.1 0.48 DIMA-Amidoamine 2.06 2.19 5.73 0.52 LS BSA-Acid 1.65 Agg 10.8 0.51 . DIMA-Amidoamine 1.65 2.10 4.71 0.52 DCE BSA-Acid Agg Agg 14.0 0.66 DIMA-Amidoamine 1.60 2.10 7.44 0.65 OB BSA-Acid 1.60 2.03 10.1 0.54 DIMA-~midoamine 1.60 2.59 2.66 0.25 FC-43 BSA-Acid Agg Agg 11.3 0.59 DIMA-~midoamine 2.03 2.54 6.04 0.62 25 FC-75 BSA-Acid 1.54 1.80 12.5 1.04 DIMA-Amidoamine 1.80 1.54 7.28 0.71 FC-77 BSA-Acid 2.06 1.54 12.1 0.86 DIMA-Amidoamine 2.06 1.52 9.83 0.71 30 Agg - Aggregated droplets.
Example 4 Emulsions were prepared with a variety of aqueous surfactants by sonication of mixtures containing 1 volume %
of FC-43 containing 0.5 weight % of either perfluoroctanoic 35 acid or perfluoroamidoamine, as in example 2, and phosphate buferad saline containing a 0.5 weight % of Emerst 2400, Triton X-100, Tween 40, Pluronic P-85, Pluronic F-38 . . ... . . . .. . .. .. . ... .. .. . . .

' (nonionic surfactants), lauric acid, Triton X-200, Emersol 6434 (anionic surfactants), Miranol C2M-SF (an ampho-teric ), r CloF2ls~o)2NH-(cH2)3-N(CH3)3cl ~a cationiC
fluorochemical surfactant) at pH 6.5 to 8.5. sefore 5 sonication BSA ~0.5~ final concentration) was added to perfluoroacid mixtures and DIMA (0.5% final concentration) was added to perfluorooamidoamine mixtures.
The emulsions were evaluated at days 1, 4, and 7 after preparation with regard to sedimentation and emulsion 10 droplet size as noted in Examples 1, 2, and 3 above. Those prepared with nonionic and amphoteric aqueous surfactants were superior to those prepared with anionic or cationic surfactants.

15 Example 5 Emulsions were prepared with 10 volume % FC-43 containing 0.5 to 1.0 weight % C~Fls C2 H in phosphate buffered saline at pH 7 with either 0.05 weight % Tween 20 or 0.1 weight % C,Fl5CO2H as a surfactant. The resultant 20 emulsions were washed using the centrifugation and resuspension procedure described in Example 3. To a 0.5 milliliter aliquot of these emulsions alkaline phosphatase (Sigma type VIIT) or Protein A ~Sigma Chemical Company) were added and incubated for 0.5 to 18 hours. The 25 emulsions were then again washed by the procedure above before being assayed for alkaline phosphatase activity with a chromogenic substrate, p-nitrophenylphosphate, or for protein A activity by agglutination with immunoglublin G
(IgG). These assays were positive for the respective 30 specific binding species demonstrating that such materials can be adsorbed to the emulsion droplet and maintain their activity.

Example 6 Emulsions were prepared as in Example 4 with the addition of 0.5 weight % of a perfluoroether polymer with terminal ester functional groups .. . . . . . . .

~3~

3 2 2 ( CF2 CF2 ) 7 ( CF2 ) 1 4 -CF2CO2CH3 (the CF2O and CF~CF2O units are randomly interspersed) in the FC-43 in place of the perfluoroacid. Alkaline phosphatase was added as in Example 5 and also was found to adsorb to the 5 emulsion droplets.

Example 7 Emulsions were prepared with 1 to 5 volume % of FC-43 containing 0.1 to 0.5 weight % each of 7 1sC(O)NH (CH2)4-N~CH3 )3 and C7F15CH2OH in solutions o~ a series of proteins, synthetic polyamino acids, and polysaccharides as listed in Table 3. The emulsions were prepared by sonication of the FC-43 mixture, addition of an equal volume of phosphate-buffered saline containing 2% by lS weight Pluronic F-68 at pH 7 and thrice washed by centrifugation at 30,000 g for 15 minutes and by resuspension in fresh surfactant-buffer solution containing no ssA.
The resulting emulsions were coupled to alkaline 20 phosphatase (Sigma Type VIIT) using either Method A, C, E
or F, listed below. With each material alkaline phosphatase activity was recovered on the emulsion droplets demonstrating both that the material was adsorbed to the droplet surface and that it was available for immobilization of enzyme antibodies or antigens. The materials thus prepared are suitable for one to detect the presence, concentration, or both of an antigen or antibody in a sample. Emulsions prepared with fibrinogen and ovalbumin tended to aggregate during the processing operations while the other materials produced more acceptable emulsions.

TAsLE 3 MATERIALS USED TO PREPARE
FLUOROCHEMICAL EMULSION-BIOMOLECULE COMBINATIONS

5 siomolecule in Concentration Aqueous Solution (mg/ml) pH
sovine Serum Albumin 0.5 to 10 7 or 0 Casein 2 to 10 12 Gelatin 2 to 10 10 Collagen 1.8 to 3.6 3 ovalbumin 2 to 5 Normal Human Serum 2 to 10 5 Fibrinogen 1 11 Protamine Sulfate 0.5 to 2.0 4 or 0 lS Poly~lysine) 0.5 to 1.0 4 or 0 Poly(phenylalanine-lysine) 0.5 4 or 0 Poly(alanine-lysine) 0.5 4 or 0 Heparin 1.0 4 Dextran Sulfate 1.0 4 Example 8 An emulsion was prepared as in Example 7 with BSA in the aqueous phase and washed as in Example 7. ~o an aliquot of this emulsion the antibody, anti-BSA, was added 25 and upon mixing aggregation of the emulsion occurred which was observed by changes (increases) in the optical density of the emulsion. Using this technique the presence of the antibody was detected and measured semi-quantitatively, using standard curves generated on a spectrophotometer.
30 This result verified that BSA was very tightly bound to the emulsion droplet surface and was antigenically active.

Example 9 An aliquot of the emulsion prepared and washed in 35 Example 8 was mixed with fluorescein-labeled anti-BSA
producing aggregation of emulsion droplets. These clumps were fluorescent as viewed by a fluorescence microscope . .

-2~-indicating that the antibody was acting to crosslink and aggregate the emulsion droplets. This result also verified that BSA is very tightly bound to the droplet surface and - was antigenically active.

Example 10 Emulsions with 1 volume ~ FC-43 containing 0.1 weight % each C,FlsCH2OH and c7Fl5c(O)NH-~cH2)q N ~ CH3 ) 2 or C7Fl5C(O)NH-C6H~N~CH3 )2 were prepared in 0.5 weight %
10 poly(phenylalanine-lysine) solution at pH 0 by sonication for 5 minutes in a rosette cell. After sonication the emulsions were stabilized with an equal volume of phosphate buffered saline containing 2.0 weight % Pluronic F-68 and 0.2 weight % triethanolamine. The dispersions were washed 15 by the procedure of Example 7 be~ore being coupled to specific binding species by one of the methods described below.
Substances which have been coupled to emulsions successfully and the methods which have been used for these 20 reactions are shown in Table 4. The substances were coupled alone or in combinations which resulted in separate specific binding activities being recovered intact on the same emulsion droplets. The materials were obtained from commercial sources as follows: Glucose Oxidase (Sigma Type 25 V), horseradish peroxidase (Sigma Type VI), alkaline phosphatase (Sigma Type VIIT), beta-galactosidase (Sigma Grade VIII), wheat germ agglutinin ~Triticum vulgaris lectin, Sigma), PHA (Phaseolus vulgaris lectin, Sigma), Protein A (Sigma), rabbit anti-goat IgG (Cappel 30 Laboratories and American Qualex), mouse anti-hCG
(Hybritech, Monoclonal), rabbit anti-HRP (Sigma), Goat IgG
~Cappel Laboratories), hCG (Sigma), luminol (Sigma), and DL-thyroxin (Sigma).
The coupled emulsions were evaluated for the 35 material immobilized by known procedures, e.g., enzymes by the assay procedures supplied by the source, antibodies with their antigens in agglutination reactions, lectins by ~o~
-25~

red blood cell agglutination, protein A by binding o~ IgG's and their reaction with antigen and luminol by reaction with peroxide and peroxidase. When combinations of materials were coupled to emulsions, separate assays for 5 each component were carried out.

Materials Coupled to Fluorochemical Emulsions Material Method Glucose Oxidase A,C,E,F
Horseradish Peroxidase E,F,I
Alkaline Phosphatase A,B,C,D,G,H
Beta-Galactosidase A
Wheat Germ Agglutinin A
Phaseolus vulgaris lectin (PHA) A
anti-~orseradish Peroxidase A
Goat Immunoglobulin G (IgG) C,E,G
anti-Goat IgG A,G
Thyroxin (T-4) D
Luminol D
Human Chorionic Gonadotropin (hCG) C,G,I
anti-hCG C,G
Protein A A
Method A
Carbodiimide Method 1.
-To 2 ml of an emulsion (1 to 2% by volume) at pH
7.0 in phosphate buffered saline containing 2% Pluronic 30 F-68 and 0.2% triethanolamine, 0.05 to 1.0 mg of the substance to be coupled was added in water solution (0.1 to 10 mg per ml) followed by 100 to 500 microliters of a carbodiimide reagent (generally 1-[3-(N,N-dimethylamino)propyl]-3-ethylcarbodiimide at 2 35 mg/ml in water). The mixture was mixed at room temperature for 1 to 2 hours and 0.5 ml each of 1.0 M glycine and 10%
ethanolamine were added and mixed for an additional two .. . .

)4~

hours. The coupled emulsion was centrifuged at 12,900 g for 30 minutes. The supernatant was discarded and the emulsion pellet resuspended in fresh surfactant buffsr.
This centrifugation and resuspension procedure was repeated 5 two more times. The resulting emulsion was then ready for use.

Method B
Carbodiimide Method 2.
The substance to be coupled to the emulsion was activated with carbodiimide reagent solution (as in Method A) at room temperature ~or 30 to 60 minutes. The ratio of car~oiimide reagent was generally in a two to five-fold molar excess. Dialysis for 2 to 6 hours at room 15 temperature with 3 buffer changes or diafiltration with 10 Yolumes of filtrate was usually satisfactory to remove excess reagent. This activated solution was then added to 2 ml of emulsion and the mixture rotated for 2 to 6 hours at room temperature. As in Method A glycine and 20 ethanolamine were then added to cap activated groups and the coupled emulsion was isolated as described in Method A.

Method C
Glutaraldehyde Method 1.
To two ml of an emulsion in saline, phosphate-buffered at pH 7.0 containing 2% Pluronic F-68 and 0.2% triethanolamine, the substance to be coupled to the emulsion, 0.05 to 1.0 mg, was added in aqueous solution (0.1 to 10 mg per ml) along with 100 to 500 microliters of 30 1% glutaraldehyde monomer solution (Sigma Chemical Co., Grade I). The mixture was then mixed at room temperature for 30 to 60 minutes. The reaction was stopped by adding 500 microliters of 10~ ethanolamine and mixed for 2 to 18 hours. Sodium borohydride, 500 microliters of 2 mg/ml in 35 water (freshly prepared), was then added and the mixture rotated for an additional 30 minutes. Clean-up by centrifugation and resuspension was carried out as specified in Method A.

~L3~8~

Method D
Glutaraldeh-~de Method 2.
The surface of 2 ml of an emulsion in surfactant buffer was activated by reaction with 250 microliters of 1%
5 glutaraldehyde monomer solution for 30 minutes and then dialyzed against surfactant buffer at 4C for 18 hours with 3 changes of buffer. Then an aqueous solution of the material ~o be coupled to the emulsion was added ~0.05 to 1.0 mg) and rotated for 18 hours. The coupling reaction 10 was stopped by addition of 500 microliters of 10%
ethanolamine and the emulsion recovered by the procedure described in Method A.

Method E
Periodate Method 1.
A solution of the substance to be coupled was dissolved in 0.3 M sodium bicarbonate at about 5 mg/ml, pH
8.1, and was activated by reaction with one milliliter of 0.6 M sodium periodate solution for 5 minutes, followed by 20 the addition of one milliliter of 0.16 M ethylene glycol solution for 30 minutes. The reaction mixture was then extensively dialyzed against 0.01 M sodium bicarbonate.
The activated material, lO0 to 200 microliters, was then added to two milliliters of emulsion; 100 microliters of 25 sodium cyanoborohydride (100 mg/ml) was added and the mixture rotated for two hours. Unreacted activated groups were then capped by reaction with 100 microliters of 10~
ethanolamine for 1 hour followed by reaction with 1 mg of sodium borohydride for another 30 minutes. The coupled 30 emulsion was then recovered by the centrifugation and resuspension procedures described in Method A.

Method F
Periodate Method 2.
To 2 ml of emulsion in surfactant buffer and 0.05 to 1.0 mg of the substance to be coupled, 200 microliters of 0.06 M sodium periodate at pH 7 and 100 microliters of .

sodium cyanoborohydride ~100 mg/ml) was added and the mixture was rotated for 1 hour. The excess re~gent was reacted with 200 microliters of 0.16 M ethylene glycol and 200 microliters of 10% ethanolamine for an hour and the 5 coupled emulsion was purified by the centrifugation and resuspension procedure of Method A.

E~ample G
Bifunctional Acid Method 1.
_ To a mixture of 2 ml of emulsion in surfactant buffer and 0.05 to 1.0 mg of substance to be coupled to the emulsion was added ~00 microliters of freshly prepared bis(N-hydroxysuccinimidyl)terephthalate solution (10 mg/ml) in N,N-dimethylformamide and the mixture was rotated for 18 15 hours. Any remaining reagent was then reacted with 500 ul of 1 M glycine and 500 ul of 10% ethanolamine for 2 hours.
The coupled emulsion was then isolated by centrifugation and resuspension in fresh buffer as in Method A.

20 Method H
Bifunctional Acid Method 2.
To a mixture of 2 ml of emulsion in surfactant buffer, was added 0.05 to 1.0 mg of substance to be coupled to the emulsion, and a 100 microliter aliquot of a mixture 25 of 10 mg of a difunctional organic acid which cannot cyclize, such as fumaric or terephthalic acid and 100 microliters of carbonyl diimidizole solution (10 mg/ml) in N,N-dimethylformamide which had reacted for 15 minutes, and the mixture was rotated for 2 hours. Excess reagent was 30 reacted with 500 microliters each of 1 M glycine and 10%
ethanolamine for 2 hours. The coupled emulsion was then isolated by centrifugation and resuspension in fresh buffer as in Method A.

35 Method I
Cyanate Method To a mixture of 2 ml of emulsion in surfactant buffer and 0.05 to 1.0 mg of material to coupled to the .. ..

.

emulsion was added 100 microl~ters o~ a p-nitrophenyl-cyanate solution (10 my/ml) in N,M-dimethylformamide, and the reaction mixture was rotated for 30 minutes at room temperature. As the reaction proceeded a yellow color 5 developed from the p-nitrophenol produced from the reaction. Then the mixture was cleaned up by the centrifugation and resuspension procedure of Method A.

Example 11 An emulsion was prepared as in Example 7 and was coupled to a mixture of glucose oxidase and horseradish peroxidase by Method E (the Periodate Method I), above.
The resulting emulsion, when exposed to glucose and substrate for peroxidase, produced color in proportion to 15 the amount of glucose present. Using o-dianisidine (0.0021 M) in O.OS M sodium acetate buffer at pH 5.1 and reference glucose solutions containing rom 50 to 500 mg per dl emulsion, the linear reference curve of absorbance at 500 nanometers vs. glucose concentration was plotted indicating 20 that the emulsion may be used to assay for glucose concentration.

Example 12 A solution of 0.2% by weight of Tiers' Blue, a 25 perfluoroalkylated copper phthalocyanine dye, in FC-43 was used to prepare emulsions of 1 to 10% by volume of perfluorotri-n butylamine in phosphate-buffered saline containing 0.5% by weight Pluronic F-68 and 2 mg/ml ssA.
The dispersions were effected by sonication for 5 to 10 30 minutes in an ice-cooled rosette cell. The emulsions were then washed by centrifugation at 30,000 g and resuspended in fresh buffersurfactant solution without BSA thrice. The resulting preparations were highly colored with a slight shift in the absorbance maximum from 610 to 612 nanometers 35 as measured by a Beckman spectrophotometer Model 35.

. . .: . .. . . . .. . .

8:1 Example 13 A solution oE C~F17SO3-C6H~N=NC6H~N~CH3)2 in perfluorotri-n-butylamine was used to prepare emulsions of 1 to 10~ by volume of perfluorotri-n-butylamine in 5 phosphate buffered saline containing 0.5% by weight Pluronic F-68 and 2 mg/ml sSA. The dispersions were e~fected by sonication for 5 to 10 minutes in an ice-cooled rosette cell. The emulsions were then washed by centrifugation at 30,000 g and resuspended in fresh 10 buffered surfactant solution without BSA thrice. The washed emulsions were yellow in color, but changed to a red when the solution pH was changed to the range of 2 to ~.
The color was associated only with the emulsion droplets, as was shown by centrifuging the emulsion at 30,000 g to 15 comple~ely remove the color from the supernatant.
Portions of the above red emulsions were combined in portions varying from 1 to 1 to 1 to 5 (by volume) of the blue emulsions from Example 12 to form several shades of purple emulsions. The combined emulsions could be 20 changed in color from purple to green by changing the pH of the aqueous solutions.

Example 14 Two milligrams of mouse immunoglobin IIg) 25 (commercially available from Cappel Laboratories, Cochranville, PA) was dissolved in 0.15 M aqueous sodium chloride solution, and glutaraldehyde was added to provide a weight percent of 1.25%. After two hours at room temperature the activated Ig was chromatographed on Bio-Gel 30 P-2 (commercially available from sioRad Laboratories, Richmond, CA) to remove excess glutaraldehyde. One milligram of the activated Ig was combined with 1 ml of a BSA emulsion from Example 7 in phosphate buffered saline of pH 9Ø After the mixture had settled for 24 hours the 35 emulsion was washed to remove unbound Ig and the emulsion tested for immunoreactivity to anti-bovine serum albumin and anti-~ouse immunoglobin by capillary immunodiffusion as .. . . . . . . . . . .

~3~ 8~

described in "Handbook of Experiment~l Immunoloyy", D.M.
Weir, ed., Vol. 1 pp. 19.1- 19.5, 81ack~ell Scientific Publications (1973). The results of the evaluation are shown in Table 5. When a solution of antibody is mixed 5 with its corresponding antiserum, the antigen combines with the antibody, and if conditions are suitable, the reactants form precipitating or flocculating aggregates which are readily vi~ible to the naked eye.

~3~
~3~-, ~ .c .,, ." ~ ~ .,~
~i 3 Ll ~: ~
~ o C
o ,~ o ~ ~n C
o~ ,, o~ ~
~3 all ~¢ H

U~

~ O ~
O-r~ +
0~1 ~rdm~

U~ ~ O

~! ~3 o 0~ rl ~ ~n c: Ei o ,t ,1 ~
~ E3 m ~

o ~a ~r~
o .,~ ~
aJ ~ .4 ~ ~ ~ o :~ '' e o O
I
.,, .,~ ~, ... ..
~ ~ a~ J~

- :

~3091~

Example 15 -A sample of the fluorochemical emulsion from Example 7 was conjugated using the method of Example 14 with Streptococcus A- carbohydrate prepared by the method described in Stanford Medical Bulletin 13, 290-291. The ability of free Streptococcus A organisms to inhibit the aggregation of the fluorochemical emulsion-bound Streptococcus A-carbohydrate mixture in the presence of an IgM monoclonal antibody was tested. A combination of the fluorochemical emulsion-bound Streptococcus A-carbohydrate, the antibody and varying concentrations o~ free Streptococcus A organisms was incubated for 30 minutes at about 20C and observed for aggregation. Aggregation was scored on a scale of zero to 4+, with zero being no inhibition o droplet aggregation and 4+ complete inhibition of droplet aggregation. The results are shown in Table 6. They indicate that this method is able to detect organisms at a level of 105 per milliliter.

TAsLE ~

Concentration of Aggregation Organisms Inhibition Run Number (organisms/ml) Score 25 1 10~ 4+
2 107 4+
3 1o6 3+
4 5 x 105 3+
105 1+
6 5 x 104 0 . . .. . . .

Claims (6)

1. An in vitro specific binding process comprising:
a. providing in vitro an emulsion comprising an aqueous continuous phase, a fluorochemical droplet discontinuous phase comprising a fluorochemical liquid and a fluorinated surfactant soluble in said fluorochemical liquid, and a specific binding species immobilized on the fluorochemical droplets, wherein the emulsion is substantially stable to centrifugation at 30,000 x g for 15 minutes; and b. contacting the fluorochemical droplets and immobilized specific binding species with an aqueous solution containing the specific binding partner of the specific binding species for a period of time sufficient to permit binding between the specific binding species and the specific binding partner.
2. A process according to claim 1 wherein the surfactant is selected from the group consisting of perfluorinated alkanoic acids and amidoacid derivatives thereof, 1,1-dihydroperfluoro-alcohols, and perfluoroether polymers with terminal ester functional groups.
3. A process according to claim 2 wherein the alkanoic acid is perfluorohexanoic acid or perfluorooctanoic acid, the alcohol is 1,1-dihydroperfluoro-n-octanol, and the polymer has the formula CH3O2CCF2O-(CF2CF2O)7(CF2O)14-CF2CO2CH3 wherein the CF2O and CF2CF2O units are randomly interspersed.
4. A process according to claim 1 wherein the surfactant is present in an amount from about 0.01% to about 5.0% by weight of the weight of the fluorochemical liquid.
5. A process according to claim 4 wherein the surfactant is present in an amount from about 0.1% to about 1.0% by weight of the weight of the fluorochemical liquid.
6. A process according to claim 1 wherein the droplets also have immobilized on their surface one or more other components of a specific binding reaction scheme selected from the group consisting of (a) dyes, (b) fluorescent molecules, and (c) components which in specific binding reaction schemes can be used to produce color, fluorescence, phosphorescence, chemiluminescence or other detectable products.
CA000541959A 1986-08-07 1987-07-14 Stable biologically active fluorochemical emulsions Expired - Fee Related CA1304681C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89401086A 1986-08-07 1986-08-07
US894,010 1986-08-07

Publications (1)

Publication Number Publication Date
CA1304681C true CA1304681C (en) 1992-07-07

Family

ID=25402480

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000541959A Expired - Fee Related CA1304681C (en) 1986-08-07 1987-07-14 Stable biologically active fluorochemical emulsions

Country Status (6)

Country Link
US (1) US5401634A (en)
EP (1) EP0257758B1 (en)
JP (1) JPS6354932A (en)
CA (1) CA1304681C (en)
DE (1) DE3784592T2 (en)
ES (1) ES2044933T3 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279558A (en) * 1989-06-16 1994-01-18 Science Incorporated Fluid delivery apparatus with an additive
US5385546A (en) * 1992-06-24 1995-01-31 Science Incorporated Mixing and delivering system
US5236418A (en) * 1992-12-07 1993-08-17 Science Incorporated Fluid mixing and delivery apparatus
US6548046B1 (en) * 1995-06-08 2003-04-15 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US6821506B2 (en) * 1995-06-08 2004-11-23 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US5773238A (en) * 1995-07-07 1998-06-30 Shukla; Ashok K. Droplet chemical reaction chamber
FI101543B (en) 1996-12-17 1998-07-15 Orion Yhtymae Oy Binding of solid phase biomolecules
US5779944A (en) * 1997-10-10 1998-07-14 Isp Investments Inc. Water dispersible perfluoroether polymer encapsulates
WO2000000630A1 (en) * 1998-06-26 2000-01-06 Shukla Ashok K Droplet reaction chamber
US7220401B2 (en) * 1999-09-24 2007-05-22 Barnes-Jewish Hospital Blood clot-targeted nanoparticles
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7179449B2 (en) 2001-01-30 2007-02-20 Barnes-Jewish Hospital Enhanced ultrasound detection with temperature-dependent contrast agents
US7811594B2 (en) * 2002-03-28 2010-10-12 Beiersdorf Ag Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions
GB0307403D0 (en) * 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
AU2004263136A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
DE102008018180A1 (en) * 2008-04-02 2009-10-15 Hansgrohe Ag Method for quantitative detection of perfluorinated surfactant e.g. perfluorinated alkylsulfonate contained in sewage sludge, involves determining interaction product formed by mixing perfluorinated surfactants and chromophore
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
DE102011007799A1 (en) * 2011-04-20 2012-10-25 Hansgrohe Ag Method for the detection of partially fluorinated surfactants

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT317424B (en) * 1971-06-09 1974-08-26 Boehringer Mannheim Gmbh Process for the production of carrier-bound proteins
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US3843443A (en) * 1973-03-30 1974-10-22 J Fishman Polypeptide materials bound to fluorocarbon polymers
GB1463513A (en) * 1974-08-13 1977-02-02 Beecham Group Ltd Enzymes
US4252827A (en) * 1979-05-23 1981-02-24 The Green Cross Corporation Oxygen-transferable fluorocarbon emulsion
JPS5719660A (en) * 1980-07-09 1982-02-01 Fuji Photo Film Co Ltd Microcapsule for immune reaction
JPS5719662A (en) * 1980-07-09 1982-02-01 Fuji Photo Film Co Ltd Preparation of microcapsule reagent for immune reaction
US4397870A (en) * 1982-07-27 1983-08-09 The University Of Pennsylvania Process for prolonging retention of emulsion particles in the bloodstream
US4423077A (en) * 1982-07-27 1983-12-27 The University Of Pennsylvania Perfluorochemical emulsion artificial blood
DE3376223D1 (en) * 1982-07-29 1988-05-11 Shimadzu Corp A bioreactor and a process for the production thereof
JPS5968344A (en) * 1982-10-12 1984-04-18 Agency Of Ind Science & Technol Unsymmetrical functional membrane and production thereof
US4514500A (en) * 1982-11-19 1985-04-30 General Electric Company Cell growth on liquid-liquid interfaces
US4605630A (en) * 1983-07-27 1986-08-12 Cooper Lipotech Inc. Large-liposome agglutination reagent and method
US4634681A (en) * 1984-10-29 1987-01-06 General Electric Company Diagnostic method of determining the presence or absence of select proteins in a liquid sample
US4619904A (en) * 1984-10-29 1986-10-28 General Electric Company Agglutinating immunoassay using protein-coated liquid droplets
US4722898A (en) * 1985-04-29 1988-02-02 Minnesota Mining And Manufacturing Company Immobilization of biological cells in polytetrafluoroethylene matrix
JPH0650315B2 (en) * 1985-11-08 1994-06-29 株式会社日立製作所 Immunological analysis reagent and immunological analysis method

Also Published As

Publication number Publication date
ES2044933T3 (en) 1994-01-16
AU7554187A (en) 1988-02-11
JPS6354932A (en) 1988-03-09
EP0257758B1 (en) 1993-03-10
DE3784592T2 (en) 1993-09-23
US5401634A (en) 1995-03-28
EP0257758A2 (en) 1988-03-02
DE3784592D1 (en) 1993-04-15
EP0257758A3 (en) 1988-11-09
AU590097B2 (en) 1989-10-26

Similar Documents

Publication Publication Date Title
CA1304681C (en) Stable biologically active fluorochemical emulsions
US4636479A (en) Enhanced agglutination method and kit
US4605630A (en) Large-liposome agglutination reagent and method
FI102921B (en) Method for Preparation of Biologically Active Reagents in Socks from iimide-Containing Polymers, Analytical Element and Methods for Using Them
CA1231049A (en) Protected binding assay
EP0014530B1 (en) Method for detecting and determining proteinaceous specific binding agents and materials bindable thereto, test composition and testkit therefor
US6653066B1 (en) Device and method for detecting polyvalent substances
FI67264B (en) REFERENCE TO A RESULT OF REFERRAL ACT
EP0110640B1 (en) Receptor-based histamine assay
EP1064552B1 (en) Immunoassays using casein coating of particles
US5276146A (en) Liquid perfluorocarbon supports useful as liquid affinity supports
EP0246103B1 (en) Bioaffinity and ion exchange separations with liquid exchange supports
Singh Dendrimer‐Based Biological Reagents: Preparation and Applications in Diagnostics
JP2749104B2 (en) Reagents for immunochemical assays containing amine oxides
US5268307A (en) Preparation of liquid affinity supports for bioaffinity an ion exchange separations
JP3106822B2 (en) Complement number measuring method and reagents used therefor
JPH0740031B2 (en) Immunological measurement method
JP3618909B2 (en) Immunoassay reagents and immunoassays
JPH03218465A (en) Production of syphilis diagnostic reagent
EP0280556A2 (en) Water-insoluble particle and immunoreactive reagent, analytical elements and methods of use
JPH02231566A (en) Enzyme labeled receptor composition, diagnosis kit and utilization thereof for ligand measurement
JPH10260187A (en) Measuring method and measuring reagent for antibody specific to common antigen determinant of antigen in which a plurality of subtype exists
JPH0933528A (en) Reaction reagent for immunoassay and production thereof

Legal Events

Date Code Title Description
MKLA Lapsed